Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Therapeutic Values of Il-7/Il-7R and the Recombinant Derivatives in Glioma: A Narrative Review Publisher Pubmed



Hesari M1 ; Attar Z2, 3 ; Soltanishirazi S4 ; Keshavarzian O5 ; Taheri R6 ; Tabrizi R7 ; Fouladseresht H4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Tabriz University of Medical Sciences, Tabriz, Iran
  2. 2. Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  3. 3. Department of Pharmacology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
  4. 4. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Shiraz University of Medical Sciences, Shiraz, Iran
  6. 6. Department of Neurosurgery, Fasa University of Medical Sciences, Fasa, Iran
  7. 7. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran

Source: Journal of Interferon and Cytokine Research Published:2023


Abstract

Interleukin-7 (IL-7) is essential for maintaining the immune system’s defense functions by regulating the development and homeostasis of lymphocytes. Findings have shown the high efficacy of IL-7/IL-7 receptor (IL-7R)-based immunotherapy on various malignancies, with confirmation in both animal models and humans. In recent years, the progression-free survival and overall survival of patients suffering from gliomas significantly increased by introducing C7R-expressing chimeric antigen receptor (CAR)-T cells and long-acting IL-7 agonists such as NT-I7 (rhIL-7-hyFc, Efineptakin alfa). However, the effect of IL-7-based immunotherapies on the resistance of tumor cells to chemotherapy (when used simultaneously with chemotherapy agents) is still ambiguous and requires further studies. This article first reviews the pathophysiological roles of IL-7/IL-7R in tumors, focusing on gliomas. Subsequently, it discusses the therapeutic values of IL-7/IL-7R and the recombinant derivatives in gliomas. © Mary Ann Liebert, Inc.
Related Docs
1. Oncolytic Virotherapy Improves Immunotherapies Targeting Cancer Stemness in Glioblastoma, Biochimica et Biophysica Acta - General Subjects (2024)
2. Genetically Engineered Mesenchymal Stem Cells: Targeted Delivery of Immunomodulatory Agents for Tumor Eradication, Cancer Gene Therapy (2020)
3. Glioblastoma Multiforme: Insights Into Pathogenesis, Key Signaling Pathways, and Therapeutic Strategies, Molecular Cancer (2025)
4. Statins: A New Approach to Combat Temozolomide Chemoresistance in Glioblastoma, Journal of Investigative Medicine (2018)
5. The Evaluation of Tlyp-1-Bound Mda-7/Il-24 Killing Activity on a Liver Tumor Cell Line, Cancer Biotherapy and Radiopharmaceuticals (2021)
6. Mda-7/Interleukin 24 (Il-24) in Tumor Gene Therapy: Application of Tumor Penetrating/Homing Peptides for Improvement of the Effects, Expert Opinion on Biological Therapy (2019)
7. Targeting Glioma Cells With Nutraceuticals: Therapeutic Effects Based on Molecular Mechanisms, New Evidence and Perspectives, Mini-Reviews in Medicinal Chemistry (2023)
8. An Immunohistochemical Study of Cyclin D1 Expression in Astrocytic Tumors and Its Correlation With Tumor Grade, Iranian Journal of Pathology (2019)
Experts (# of related papers)
View all Related Experts
Parvin Mahzouni (1)
Rasoul Salehi (1)